Search results
May 28, 2014 · For more than 20 years, Bedford Laboratories and its product portfolio have been of great value to patients, customers and the marketplace. As part of Hikma, the Bedford team will remain focused on strengthening its relationships with customers and continuing to serve the needs of patients."
The Bedford Lab at the Fred Hutch works at the interface of evolution, epidemiology and virology. We apply computational and statistical methods to sequence data to understand viral dynamics, and reconstruct patterns of epidemic growth and geographic spread.
May 30, 2014 · Hikma is buying Bedford Laboratories from Boehringer Ingelheim for $300 million. Hikma is also in talks to buy BI’s Ohio-based manufacturing facility. After the acquisition, Hikma will become the company with the largest portfolio of generic injectables in the US.
Jul 15, 2014 · Hikma is acquiring Bedford’s large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong R&D and business development pipeline and a number of employees across key business functions.
May 29, 2014 · Hikma Pharmaceuticals, a multinational pharmaceutical group headquartered in Amman, Jordan, has agreed with Ben Venue Laboratories, a division of Boehringer Ingelheim, to buy the assets of Bedford Laboratories, its US generic injectables business.
Jul 16, 2014 · Hikma Pharmaceuticals, a multinational pharmaceutical group headquartered in Amman, Jordan, has completed its US$300m acquisition of assets of the US generic injectables business, Bedford Laboratories, from Ben Venue Laboratories, a member of the Boehringer Ingelheim Group.
May 29, 2014 · Hikma will acquire assets of Bedford Laboratories for a total consideration of up to $300 million, which includes an upfront cash payment of $225 million and a further $75 million in contingent cash payments, subject to the achievement of performance-related milestones over a period of five years.
